The Efficacy and Safety of Combined Teriflunomide and High-dose Dexamethasone in Newly Diagnosed Primary Immune Thrombocytopenia (TEMPO-2)

Abroad (travel likely)RecruitingPHASE2

Conditions

Immune Thrombocytopenia (ITP)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Peking University First Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Yu-Jun Dong, MD) · dongy@hsc.pku.edu.cn · +8618210264969
Peking University Insititute of Hematology, Peking University People's Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Xiao-Hui Zhang, MD) · zhangxh@bjmu.edu.cn · +8613522338836
Contact: Study coordinator (Li-Ping Yang, MD) · lpyang@bjmu.edu.cn · +8618519172033
Peking University Third Hospital, Beijing, Beijing Municipality, China
Contact: Study coordinator (Hong-Mei Jing, MD) · hongmeijing@bjmu.edu.cn · +8615611908428

Study leads

Xiao-Hui Zhang, MD
Principal Investigator
Peking University Institute of Hematology, Peking University People's Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Romiplostim N01 Combined With Glucocorticoids as the First-line Treatment for Newly Diagnosed Adult Primary Immune Thrombocytopenia: A Multicenter, Interventional Trial

Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE2

Tianjin, China

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE3

Jinan, China

Safety, Tolerability, and Efficacy of NVG-2089 in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)

Abroad (travel likely)RecruitingPHASE2

Greenville, United States

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

Immune Thrombocytopenia · Treatment

Abroad (travel likely)RecruitingPHASE2

Tianjin, China